Effects of drugs commonly used in Sars-CoV-2 infection on renal tissue in rats

Aim: In December 2019, the coronavirus disease was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some drugs were repurposed for this disease treatment. Hydroxychloroquine (HCQ), favipiravir (FAV), molnupiravir (MOL), and dexamethasone (DEX) were widely used for the treatment of the disease. To increase the success of the treatment of coronavirus disease, there was used some of these drugs in combination. On the other hand, limited studies report these drugs’ side effects. Therefore, this study was designed to evaluate the possible effects of these drugs and their combinations on the kidney tissues of rats without viral load. Materials and Methods: Male Wistar albino rats were divided into control, HCQ, FAV, HCQ+FAV, HCQ+FAV+DEX, MOL, and MOL+DEX groups. At the end of the experiment, the serum kidney tissue samples were taken. Serum samples were analyzed for urea and creatinine. Kidney tissue samples were assessed as histopathological and immunohistochemical for heat shock protein 60 (HSP60), caspase-3, and receptor-interacting protein kinase-3 (RIPK3). Results: Urea and creatinine levels were within the normal range in all groups. Histopathologically, all drugs and their combinations caused tubular degeneration. On the other hand, histopathological alterations were more prominent in the HCQ group. The oxidative stress marker HSP60 was significantly increased in FAV, MOL, and MOL+DEX groups, while it was similar to the control group in the HCQ groups. Apoptosis marker caspase-3 expression was found to be prominently higher in other drug groups except the FAV group. Expression of RIPK3, a marker of necroptosis, was significantly increased in all drug groups. Conclusion: Taken together, the data of our study show that the administration of all drugs alone and in combination may cause structural damage to the kidney. Furthermore, our results indicate that HCQ can exhibit more damaging effects compared to other drugs.

Anahtar Kelime: SARS-CoV-2 Hydroxychloroquine Favipiravir Molnupiravir Dexamethason Kidney damage

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Zhang JJ, Dong X, Liu GH, Gao YD. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. Clinical reviews in allergy & immunology. 2023;64(1):90-107. https://doi.org/10.1007/s12016-022-08921-5.
2. Jain U. Effect of COVID-19 on the Organs. Cureus. 2020;12(8):e9540. https://doi.org/10.7759/cureus.9540.
3. Gavriatopoulou M, Korompoki E, Fotiou D, et al. Organ-specific manifestations of COVID-19 infection. Clinical and experimental medicine. 2020;20(4):493-506. https://doi.org/10.1007/s10238- 020-00648-x.
4. Amann K, Boor P, Wiech T, et al. COVID-19 effects on the kidney. Der Pathologe. 2021;42(Suppl 1):76-80. https://doi.org/10.1007/s00292-020-00900-x.
5. Abdelbary AA, Alharafsheh AE, Ahmed A, Nashwan AJ. Favipiravir-induced nephrotoxicity in a patient with COVID19: A case report. Clinical case reports. 2021;9(8):e04539. https://doi.org/10.1002/ccr3.4539.
6. Wen W, Chen C, Tang J, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: A meta analysis. Annals of medicine.2022;54(1):516-23. https://doi.org/10.1080/07853890.2022.2034936.
7. Yunusoğlu O. The rationale for current pharmacotherapy of Covid19. East J Med. 2020;25(3). https://doi.org/10.5505/ejm.2020.29053.
8. Sinha N, Balayla G. Hydroxychloroquine and COVID19. Postgraduate medical journal. 2020;96(1139):550-5. https://doi.org/10.1136/postgradmedj-2020-137785.
9. Law MF, Ho R, Law KWT, Cheung CKM. Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases. World journal of hepatology. 2021;13(12):1850-74. https://doi.org/10.4254/wjh.v13.i12.1850.
10. Konstantinova ID, V LA, Fateev IV, Esipov RS. Favipiravir and Its Structural Analogs: Antiviral Activity and Synthesis Methods. Acta naturae. 2022;14(2):16-38. https://doi.org/10.32607/actanaturae.11652.
11. Allahverdiyeva S, Yunusoğlu O, Yardım Y, Şentürk Z. First electrochemical evaluation of favipiravir used as an antiviral option in the treatment of COVID-19: A study of its enhanced voltammetric determination in cationic surfactant media using a boron-doped diamond electrode. Analytica Chimica Acta. 2021;1159:338418. https://doi.org/10.1016/j.aca.2021.338418.
12. Kaur RJ, Charan J, Dutta S, et al. Favipiravir Use in COVID19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database. Infection and drug resistance. 2020;13:4427-38. https://doi.org/10.2147/idr.s287934.
13. Wallace KB, Bjork JA. Molnupiravir; molecular and functional descriptors of mitochondrial safety. Toxicology and applied pharmacology. 2022;442:116003. https://doi.org/10.1016/j.taap.2022.116003.
14. Singh AK, Singh A, Singh R, Misra A. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Diabetes & metabolic syndrome. 2022;16(2):102396. https://doi.org/10.1016/j.dsx.2022.102396.
15. Yücel HE. A case of acute renal failure with COVID-19 under Molnupiravir treatment. Medical Science and Discovery. 2022;9(6):371-4. https://doi.org/10.36472/msd.v9i6.749.
16. Johnson RM, Vinetz JM. Dexamethasone in the management of covid-19. British Medical Journal Publishing Group; 2020.
17. Chen F, Hao L, Zhu S, et al. Potential Adverse Effects of Dexamethasone Therapy on COVID-19 Patients: Review and Recommendations. Infectious diseases and therapy. 2021;10(4):1907-31. https://doi.org/10.1007/s40121-021-00500-z.,
18. Çolak C, PARLAKPINAR H. Hayvan deneyleri: in vivo denemelerin bildirimi: ARRIVE Kılavuzu-Derleme. Journal of Turgut Ozal Medical Center. 2012;19(2):128-31.
19. Arslan AK, Çiçek IB, Çolak C, editors. Open source web based software for random assignment/allocation methods in data processing. 2019 International Artificial Intelligence and Data Processing Symposium (IDAP), 21-22 September 2019. Malatya, Türkiye, 1-4.
20. Arslan AK, Yaşar Ş, Çolak C, Yoloğlu S. WSSPAS: an interactive web application for sample size and power analysis with R using shiny. Türkiye Klinikleri Biyoistatistik. 2018;10(3):224-46. https://doi.org/10.5336/biostatic.2018-62787.
21. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. Journal of basic and clinical pharmacy. 2016;7(2):27-31. https://doi.org/10.4103/0976- 0105.177703.
22. Elbe H, Dogan Z, Taslidere E, et al. Beneficial effects of quercetin on renal injury and oxidative stress caused by ciprofloxacin in rats: A histological and biochemical study. Human & experimental toxicology. 2016;35(3):276-81. https://doi.org/10.1177/0960327115584686.
23. Yildiz A, Ozhan O, Ulu A, et al. Effects of the apricot diets containing sulfur dioxide at different concentrations on rat testicles. Environmental science and pollution research international. 2023;30(29):74301-13. https://doi.org/10.1007/s11356- 023-27692-w.
24. Kale A, Shelke V, Dagar N, et al. How to use COVID19 antiviral drugs in patients with chronic kidney disease. Frontiers in pharmacology. 2023;14:1053814. https://doi.org/10.3389/fphar.2023.1053814.
25. Thammitiyagodage MG, de Silva NR, Rathnayake C, et al. Biochemical and histopathological changes in Wistar rats after consumption of boiled and un-boiled water from high and low disease prevalent areas for chronic kidney disease of unknown etiology (CKDu) in north Central Province (NCP) and its comparison with low disease prevalent Colombo, Sri Lanka. BMC nephrology. 2020;21(1):38. https://doi.org/10.1186/s12882-020- 1693-3.
26. Szyller J, Bil-Lula I. Heat Shock Proteins in Oxidative Stress and Ischemia/Reperfusion Injury and Benefits from Physical Exercises: A Review to the Current Knowledge. Oxidative medicine and cellular longevity. 2021;2021:6678457. https://doi.org/10.1155/2021/6678457.
27. Wan Q, Song D, Li H, He ML. Stress proteins: the biological functions in virus infection, present and challenges for targetbased antiviral drug development. Signal transduction and targeted therapy. 2020;5(1):125. https://doi.org/10.1038/s41392- 020-00233-4.
28. Gunaydin-Akyildiz A, Aksoy N, Boran T, et al. Favipiravir induces oxidative stress and genotoxicity in cardiac and skin cells. Toxicology letters. 2022;371:9-16. https://doi.org/10.1016/j.toxlet.2022.09.011.
29. Doğan MF, Kaya K, Demirel HH, et al. The effect of vitamin C supplementation on favipiravir-induced oxidative stress and proinflammatory damage in livers and kidneys of rats. Immunopharmacology and immunotoxicology. 2023:1-24. https://doi.org/10.1080/08923973.2023.2181712.
30. Kara A, Yakut S, Caglayan C, et al. Evaluation of the toxicological effects of favipiravir (T-705) on liver and kidney in rats: biochemical and histopathological approach. Drug and chemical toxicology. 2023;46(3):546-56. https://doi.org/10.1080/01480545.2022.2066116.
31. Brandsma I, Derr R, Zhang G, et al. Genotoxicity assessment of potentially mutagenic nucleoside analogues using ToxTracker®. Toxicology letters. 2022;362:50-8. https://doi.org/10.1016/j.toxlet.2022.04.002.
32. Kobayashi H, Mori Y, Ahmed S, et al. Oxidative DNA damage by N4-hydroxycytidine, a metabolite of the SARS-CoV-2 antiviral molnupiravir. The Journal of infectious diseases. 2022. https://doi.org/10.1093/infdis/jiac477.
33. Ercal N, Gurer-Orhan H, Aykin-Burns N. Toxic metals and oxidative stress part I: mechanisms involved in metal-induced oxidative damage. Current topics in medicinal chemistry. 2001;1(6):529-39. https://doi.org/10.2174/1568026013394831.
34. Leong XF. Lipid Oxidation Products on InflammationMediated Hypertension and Atherosclerosis: A Mini Review. Frontiers in nutrition. 2021;8:717740. https://doi.org/10.3389/fnut.2021.717740.
35. Mishima E, Anzai N, Miyazaki M, Abe T. Uric Acid Elevation by Favipiravir, an Antiviral Drug. The Tohoku journal of experimental medicine. 2020;251(2):87-90. https://doi.org/10.1620/tjem.251.87.
36. Santi Laurini G, Montanaro N, Motola D. Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data. Journal of Clinical Medicine. 2023;12(1):34. https://doi.org/10.3390/jcm12010034.
37. Hall AM, Trepiccione F, Unwin RJ. Drug toxicity in the proximal tubule: new models, methods and mechanisms. Pediatric nephrology (Berlin, Germany). 2022;37(5):973-82. https://doi.org/10.1007/s00467-021-05121-9.
38. Smith CC, Yellon DM. Necroptosis, necrostatins and tissue injury. Journal of cellular and molecular medicine. 2011;15(9):1797-806. https://doi.org/10.1111/j.1582- 4934.2011.01341.x.
39. Elmore S. Apoptosis: a review of programmed cell death. Toxicologic pathology. 2007;35(4):495-516. https://doi.org/10.1080/01926230701320337.
40. Dhuriya YK, Sharma D. Necroptosis: a regulated inflammatory mode of cell death. Journal of neuroinflammation. 2018;15(1):199. https://doi.org/10.1186/s12974-018-1235-0.
41. Priante G, Gianesello L, Ceol M, et al. Cell Death in the Kidney. International journal of molecular sciences. 2019;20(14). https://doi.org/10.3390/ijms20143598.
42. Zhu Y, Cui H, Xia Y, Gan H. RIPK3-Mediated Necroptosis and Apoptosis Contributes to Renal Tubular Cell Progressive Loss and Chronic Kidney Disease Progression in Rats. PloS one. 2016;11(6):e0156729. https://doi.org/10.1371/journal.pone.0156729.
43. Klouda CB, Stone WL. Oxidative Stress, Proton Fluxes, and Chloroquine/Hydroxychloroquine Treatment for COVID-19. Antioxidants (Basel, Switzerland). 2020;9(9). https://doi.org/10.3390/antiox9090894.
44. El Shishtawy MA, Hassan KH, Ramzy R, et al. Comparative toxicity study of chloroquine and hydroxychloroquine on adult albino rats. Eur Sci J. 2015;1:399-407.
45. Ertuğrul A, Özkaya D, Nazıroğlu M. Curcumin attenuates hydroxychloroquine-mediated apoptosis and oxidative stress via the inhibition of TRPM2 channel signalling pathways in a retinal pigment epithelium cell line. Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2023:1- 16. https://doi.org/10.1007/s00417-023-06082-5.
46. Edelstein CL, Venkatachalam MA, Dong Z. Autophagy inhibition by chloroquine and hydroxychloroquine could adversely affect acute kidney injury and other organ injury in critically ill patients with COVID-19. Kidney international. 2020;98(1):234- 5. https://doi.org/10.1016/j.kint.2020.05.001.
47. Feng YL, Tang XL. Effect of glucocorticoid-induced oxidative stress on the expression of Cbfa1. Chemico-biological interactions. 2014;207:26-31. https://doi.org/10.1016/j.cbi.2013.11.004
48. Sato H, Takahashi T, Sumitani K, et al. Glucocorticoid Generates ROS to Induce Oxidative Injury in the Hippocampus, Leading to Impairment of Cognitive Function of Rats. Journal of clinical biochemistry and nutrition. 2010;47(3):224-32. https://doi.org/10.3164/jcbn.10-58.
49. Chen Y, Luan L, Wang C, et al. Dexmedetomidine protects against lipopolysaccharide-induced early acute kidney injury by inhibiting the iNOS/NO signaling pathway in rats. Nitric oxide : biology and chemistry. 2019;85:1-9. https://doi.org/10.1016/j.niox.2019.01.009.
50. Kang K, Gao Y, Wang SC, et al. Dexmedetomidine protects against lipopolysaccharide-induced sepsis-associated acute kidney injury via an α7 nAChR-dependent pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2018;106:210-6. https://doi.org/10.1016/j.biopha.2018.06.059.

APA	Yıldız A, Ozhan O, Vardi N, AKYÜZ M, BAKAR B, Ulu A, Taslidere E, KÜÇÜKAKÇALI Z, Ates B, Parlakpinar H (2023). Effects of drugs commonly used in Sars-CoV-2 infection on renal tissue in rats. , 1209 - 1216. 10.5455/annalsmedres.2023.08.180
Chicago	Yıldız Azibe,Ozhan Onural,Vardi Nigar,AKYÜZ Mustafa,BAKAR Busra,Ulu Ahmet,Taslidere Elif,KÜÇÜKAKÇALI ZEYNEP,Ates Burhan,Parlakpinar Hakan Effects of drugs commonly used in Sars-CoV-2 infection on renal tissue in rats. (2023): 1209 - 1216. 10.5455/annalsmedres.2023.08.180
MLA	Yıldız Azibe,Ozhan Onural,Vardi Nigar,AKYÜZ Mustafa,BAKAR Busra,Ulu Ahmet,Taslidere Elif,KÜÇÜKAKÇALI ZEYNEP,Ates Burhan,Parlakpinar Hakan Effects of drugs commonly used in Sars-CoV-2 infection on renal tissue in rats. , 2023, ss.1209 - 1216. 10.5455/annalsmedres.2023.08.180
AMA	Yıldız A,Ozhan O,Vardi N,AKYÜZ M,BAKAR B,Ulu A,Taslidere E,KÜÇÜKAKÇALI Z,Ates B,Parlakpinar H Effects of drugs commonly used in Sars-CoV-2 infection on renal tissue in rats. . 2023; 1209 - 1216. 10.5455/annalsmedres.2023.08.180
Vancouver	Yıldız A,Ozhan O,Vardi N,AKYÜZ M,BAKAR B,Ulu A,Taslidere E,KÜÇÜKAKÇALI Z,Ates B,Parlakpinar H Effects of drugs commonly used in Sars-CoV-2 infection on renal tissue in rats. . 2023; 1209 - 1216. 10.5455/annalsmedres.2023.08.180
IEEE	Yıldız A,Ozhan O,Vardi N,AKYÜZ M,BAKAR B,Ulu A,Taslidere E,KÜÇÜKAKÇALI Z,Ates B,Parlakpinar H "Effects of drugs commonly used in Sars-CoV-2 infection on renal tissue in rats." , ss.1209 - 1216, 2023. 10.5455/annalsmedres.2023.08.180
ISNAD	Yıldız, Azibe vd. "Effects of drugs commonly used in Sars-CoV-2 infection on renal tissue in rats". (2023), 1209-1216. https://doi.org/10.5455/annalsmedres.2023.08.180

APA	Yıldız A, Ozhan O, Vardi N, AKYÜZ M, BAKAR B, Ulu A, Taslidere E, KÜÇÜKAKÇALI Z, Ates B, Parlakpinar H (2023). Effects of drugs commonly used in Sars-CoV-2 infection on renal tissue in rats. Annals of Medical Research, 30(10), 1209 - 1216. 10.5455/annalsmedres.2023.08.180
Chicago	Yıldız Azibe,Ozhan Onural,Vardi Nigar,AKYÜZ Mustafa,BAKAR Busra,Ulu Ahmet,Taslidere Elif,KÜÇÜKAKÇALI ZEYNEP,Ates Burhan,Parlakpinar Hakan Effects of drugs commonly used in Sars-CoV-2 infection on renal tissue in rats. Annals of Medical Research 30, no.10 (2023): 1209 - 1216. 10.5455/annalsmedres.2023.08.180
MLA	Yıldız Azibe,Ozhan Onural,Vardi Nigar,AKYÜZ Mustafa,BAKAR Busra,Ulu Ahmet,Taslidere Elif,KÜÇÜKAKÇALI ZEYNEP,Ates Burhan,Parlakpinar Hakan Effects of drugs commonly used in Sars-CoV-2 infection on renal tissue in rats. Annals of Medical Research, vol.30, no.10, 2023, ss.1209 - 1216. 10.5455/annalsmedres.2023.08.180
AMA	Yıldız A,Ozhan O,Vardi N,AKYÜZ M,BAKAR B,Ulu A,Taslidere E,KÜÇÜKAKÇALI Z,Ates B,Parlakpinar H Effects of drugs commonly used in Sars-CoV-2 infection on renal tissue in rats. Annals of Medical Research. 2023; 30(10): 1209 - 1216. 10.5455/annalsmedres.2023.08.180
Vancouver	Yıldız A,Ozhan O,Vardi N,AKYÜZ M,BAKAR B,Ulu A,Taslidere E,KÜÇÜKAKÇALI Z,Ates B,Parlakpinar H Effects of drugs commonly used in Sars-CoV-2 infection on renal tissue in rats. Annals of Medical Research. 2023; 30(10): 1209 - 1216. 10.5455/annalsmedres.2023.08.180
IEEE	Yıldız A,Ozhan O,Vardi N,AKYÜZ M,BAKAR B,Ulu A,Taslidere E,KÜÇÜKAKÇALI Z,Ates B,Parlakpinar H "Effects of drugs commonly used in Sars-CoV-2 infection on renal tissue in rats." Annals of Medical Research, 30, ss.1209 - 1216, 2023. 10.5455/annalsmedres.2023.08.180
ISNAD	Yıldız, Azibe vd. "Effects of drugs commonly used in Sars-CoV-2 infection on renal tissue in rats". Annals of Medical Research 30/10 (2023), 1209-1216. https://doi.org/10.5455/annalsmedres.2023.08.180